U.S. Health Secretary Robert F. Kennedy Jr.'s newly revamped vaccine advisory panel voted on Thursday to recommend Americans ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

During fall and winter viral RNA was detected on 11 of 52 (21%) of toys sampled (Table 1). Ten of the 11 positives were picornavirus and 1 was influenza B; no RSV RNA was detected on samples in ...

Flu, COVID-19, and Respiratory Syncytial Virus (RSV): If you are ill with a respiratory virus, PLEASE STAY HOME and away from others. This will help everyone. If you are in the clinical portion of ...

Fiona Havers, who oversaw CDC respiratory virus data, ... led the CDC’s surveillance of hospitalizations for coronavirus and respiratory syncytial virus (RSV), ...

Queensland’s Chief Health Officer has praised the new immunisation program that has protected hundreds of Queensland babies from Respiratory Syncytial Virus (RSV), as flu and Covid-19 cases ...

Nirsevimab offers consistent and sustained protection against hospitalisation due to RSV-associated lower respiratory tract infection for at least 6 months. This finding provides global health systems ...

CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company's ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.

Merck, known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration has approved ENFLONSIA™ for the prevention of respiratory syncytial virus lower ...

U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV ...